Economic Evaluation of Transitioning to the 20-Valent Pneumococcal Conjugate Vaccine in the Dutch Paediatric National Immunisation Programme

Economic Evaluation of Transitioning to the 20-Valent Pneumococcal Conjugate Vaccine in the Dutch Paediatric National Immunisation Programme

Abstract Introduction In 2024, the vaccination strategy against pneumococcal disease in the Dutch paediatric population was changed from the 10-valent pneumococcal conjugate vaccine (PCV) (PCV10) to a 15-valent PCV (PCV15) under a 2 + 1 schedule. We aimed to assess whether switching from PCV15 under...

Full description

Saved in:
Bibliographic Details
Main Authors: Esra Çakar, An Ta, Michel Peters, Elizabeth Vinand, Angela Waterval-Overbeek, Aleksandar Ilic, Johnna Perdrizet
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-02-01
Series:Infectious Diseases and Therapy
Subjects:
Cost-effectiveness
20-valent pneumococcal conjugate vaccine
Paediatric
Netherlands
Pneumococcal disease
National Immunisation Programme
Online Access:https://doi.org/10.1007/s40121-025-01109-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40121-025-01109-2

Similar Items